耳鼻咽喉科・頭頸部外科91巻7号

2019年06月発行

特集 甲状腺腫瘍の診療最前線 《治療法の最近の動向》

分子標的薬

著者： 小山泰司¹ 清田尚臣¹²

所属機関： ¹神戸大学医学部附属病院腫瘍・血液内科 ²神戸大学医学部附属病院腫瘍センター

ページ範囲：P.572 - P.578

POINT

●分子標的薬が出現してから甲状腺癌の治療は大きく変わった。

●現在，本邦ではソラフェニブ，レンバチニブ，バンデタニブの3剤が使用可能である。

●特徴的な副作用がみられ，治療継続のためにはその対策が重要である。

●分子標的薬不応後の治療選択肢は乏しく，新規治療の開発が望まれる。

参考文献

1）Brose MS, et al：Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer：a randomised, double-blind, phase 3 trial. Lancet 384：319-328, 2014

2）Schlumberger M, et al：Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372：621-630, 2015

3）Kiyota N, et al：Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106：1714-1721, 2015

4）Wells SA Jr, et al：Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer：a randomized, double-blind phase Ⅲ trial. J Clin Oncol 30：134-141, 2012

5）de Castroneves LA, et al：Sorafenib for the treatment of progressive metastatic medullary thyroid cancer：efficacy and safety analysis. Thyroid 26：414-419, 2016.

6）Priya SR, et al：Targeted therapy for medullary thyroid cancer：a review. Front Oncol 7：238, 2018

7）Ito Y, et al：Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 27：1142-1148, 2017

8）Schlumberger M, et al：A Phase Ⅱ trial of the multitargeted tyrosine kinase inhibitor lenvatinib（E7080）in advanced medullary thyroid cancer. Clin Cancer Res 22：44-53, 2016

9）Takahashi S, et al：A Phase Ⅱ study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 15：717-726, 2019

10）Elisei R, et al：Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31：3639-3646, 2013

11）Schlumberger M, et al：Overall survival analysis of EXAM, a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 28：2813-2819, 2017

12）Tahara M, et al：Lenvatinib for anaplastic thyroid cancer. Front Oncol 7：25, 2017

13）Savvides P, et al：Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23：600-604, 2013

14）Pennell NA, et al：A phase Ⅱ study of gefitinib in patients with advanced thyroid cancer. Thyroid 18：317-323, 2008

15）Ha HT, et al：A phase Ⅱ study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20：975-980, 2010

16）Bible KC, et al：A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 97：3179-3184, 2012

17）Ren Z, et al：Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33：894-900, 2015

18）Wu S, et al：Incidence and risk of hypertension with sorafenib in patients with cancer：a systematic review and meta-analysis. Lancet Oncol 9：117-123, 2008

19）ネクサバール適正使用ガイド—甲状腺癌編　https://pharma-navi.bayer.jp/omr/online/product_material/160304_NET-16-0700.pdf［2019年1月30日閲覧］

20）適正使用ガイド—カプレルサ　https://e-mr.sanofi.co.jp/-/media/EMS/Conditions/eMR/products/caprelsa/downloads/cap_tekisei.pdf?la=ja-JP［2019年1月30日閲覧］

21）適正使用ガイド—レンビマ（甲状腺癌）　https://medical.eisai.jp/content/000000763.pdf［2019年1月30日閲覧］

22）Brinda BJ, et al：Anti-VEGF-induced hypertension：a review of pathophysiology and treatment options. Curr Treat Options Cardio Med 18：33, 2016

23）Izzedine H, et al：VEGF signalling inhibition-induced proteinuria：mechanisms, significance and management. Eur J Cancer 46：439-448, 2010

24）Izzedine H, et al：Kidney diseases associated with anti-vascular endothelial growth factor（VEGF）：an 8-year observational study at a single center. Medicine（Baltimore） 93：333-339, 2014

25）Gressett SM, et al：Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43：490-501, 2009

26）Hiremath S, et al：Renin angiotensin system blockade in kidney transplantation：a systematic review of the evidence. Am J Transplant 7：2350-2360, 2007

27）Diaz L, et al：Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann Oncol 28（suppl_5）：v122-v141, 2017　doi：10.1093/annonc/mdx367.020

28）厚生労働省：最適使用推進ガイドライン　ペムブロリズマブ（遺伝子組換え）—高頻度マイクロサテライト不安定性（MSI-High）を有する固形癌，平成30年12月　https://www.pmda.go.jp/files/000227181.pdf

29）Hause RJ, et al：Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22：1342-1350, 2016

30）Le DT, et al：Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357：409-413, 2017

31）Hale-Wallace N, et al：Genetic variants including microsatellite instability in metastatic Hürthle cell carcinoma of the thyroid. J Clin Oncol 36（15_suppl）：e18110, 2018

32）Xing M, et al：J Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. Clin Oncol 33：42-50, 2015

32）Brose MS, et al：Vemurafenib in patients with BRAF（V600E）-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine：a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17：1272-1282, 2016

34）Begum S, et al：BRAF mutations in anaplastic thyroid carcinoma：implications for tumor origin, diagnosis and treatment. Mod Pathol 17：1359-1363, 2004

35）Nikiforova MN, et al：BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88：5399-5404, 2003

36）Takano T, et al：BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96：1549-1553, 2007

37）Ghossein RA, et al：Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 98：E1414-1421, 2013

38）Subbiah V, et al：Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 36：7-13, 2018

39）Ho AL, et al：Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368：623-632, 2013

40）Cabanillas ME, et al：Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer：results of a multicenter phase Ⅱ International Thyroid Oncology Group Trial. J Clin Oncol 35：3315-3321, 2017

41）Leeman-Neill RJ, et al：ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 120：799-807, 2014

42）Drilon A, et al：Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378：731-739, 2018